Mostrando 3 resultados de: 3
Nimotuzumab induces NK cell activation, cytotoxicity, dendritic cell maturation and expansion of EGFR-specific T cells in head and neck cancer patients
ArticleAbstract: Survival benefit and long-term duration of clinical response have been seen using the epidermal growPalabras claves:head and neck cancer, Human epidermal growth factor receptor, monoclonal antibodies, Natural killer cells, T cellsAutores:Barroso M.C., Concha-Benavente F., Cuevas I., Ferris R.L., Frómeta C., García-Bates T.M., González A., Gonzalez Z., Hechavarría E., Lavastida A., Lugiollo M., Mazorra Z., Mestre B.F., Srivastava R.M., Tania Crombet, Valdés A.Fuentes:scopusNimotuzumab: beyond the EGFR signaling cascade inhibition
ReviewAbstract: One of the most known oncogenes is the epidermal growth factor receptor (EGFR) family. It activatesPalabras claves:antibody-dependent cell mediated cytotoxicity (ADCC), eGFR, HLA class I molecules, monoclonal antibodies, Natural killer cells, T cellsAutores:Chao L., Iznaga N., Lavastida A., Mazorra Z., Ramos M., Sanchez B., Tania CrombetFuentes:scopusSafety and immunogenicity of a human epidermal growth factor receptor 1 (HER1)-based vaccine in prostate castration-resistant carcinoma patients: A dose-escalation phase I study trial
ArticleAbstract: Metastatic castration-resistant prostate cancer (CRPC) remains incurable due to the lack of effectivPalabras claves:Human epidermal growth factor receptor, Immunogenicity, Prostate cancer, safety, Therapeutic vaccineAutores:Aira L.E., Bárbara Wilkinson, Caballero I., Casacó Parada A.R., Coba K., González J.G., González N., Lavastida A., Luaces P.L.o., Macías A.E., Mazorra Z., Mesa M., Popa X., Rivero J., Sanchez B., Santiesteban Y., Suárez E., Tania Crombet, Troche M.Fuentes:scopus